These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 19945649)
1. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface. Enna SJ; Williams M Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649 [No Abstract] [Full Text] [Related]
2. Billion-dollar market blossoms as botanicals take root. Glaser V Nat Biotechnol; 1999 Jan; 17(1):17-8. PubMed ID: 9920256 [No Abstract] [Full Text] [Related]
3. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
4. Market watch: upcoming market catalysts in Q2 2011. Jeng R Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455226 [No Abstract] [Full Text] [Related]
5. Market watch: upcoming market catalysts in Q1 of 2010. Rosenthal J Nat Rev Drug Discov; 2010 Jan; 9(1):11. PubMed ID: 20043022 [No Abstract] [Full Text] [Related]
6. Recent drug approvals from the US FDA and EMEA: what the future holds. Pevarello P Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069 [TBL] [Abstract][Full Text] [Related]
7. Clinical research: outlook from industry. Echols R Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942 [No Abstract] [Full Text] [Related]
8. New clinical trials policy at FDA. Vastag B Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196 [No Abstract] [Full Text] [Related]
9. Market watch: upcoming market catalysts in Q1 2013. Inui E Nat Rev Drug Discov; 2013 Jan; 12(1):12. PubMed ID: 23274459 [No Abstract] [Full Text] [Related]
10. A critical tipping point. Zuckerman MB US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366 [No Abstract] [Full Text] [Related]
11. Market watch: Upcoming market catalysts in Q3 2013. Roybal D Nat Rev Drug Discov; 2013 Jul; 12(7):496. PubMed ID: 23812261 [No Abstract] [Full Text] [Related]
12. Market watch: Upcoming market catalysts in Q4 2013. Fong S Nat Rev Drug Discov; 2013 Oct; 12(10):731. PubMed ID: 24080689 [No Abstract] [Full Text] [Related]
13. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297 [TBL] [Abstract][Full Text] [Related]
14. The United States Food and Drug Administration and the end of antibiotics. Shlaes DM; Moellering RC Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094 [No Abstract] [Full Text] [Related]
15. Experimental use and the Orphan Drug Act: a biotechnology conundrum. Koivuniemi PJ Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930 [No Abstract] [Full Text] [Related]
16. Market watch: Upcoming market catalysts in Q2 2013. Nguyen K Nat Rev Drug Discov; 2013 Apr; 12(4):254. PubMed ID: 23535926 [No Abstract] [Full Text] [Related]
17. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Kaitin KI; DiMasi JA Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382 [TBL] [Abstract][Full Text] [Related]
18. Market watch: key clinical and regulatory events in Q2 2010. Hay M Nat Rev Drug Discov; 2010 Apr; 9(4):261. PubMed ID: 20357797 [No Abstract] [Full Text] [Related]
19. Merck v. Integra: Supreme Court permits use of patented compounds to obtain Food and Drug Administration approvals. Manthei JR; Hathaway CR; Grant MA; Chung DD Food Drug Law J; 2006; 61(2):273-7. PubMed ID: 16903032 [No Abstract] [Full Text] [Related]
20. Vision and will: the future of the FDA. Epstein D Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098 [No Abstract] [Full Text] [Related] [Next] [New Search]